Incyte Q3 Revenue Rises 14% to $1.56 Billion; Guidance Trails Estimates
Incyte reported Q3 2026 revenue of $1.56 billion, up 14% year on year. Full-year revenue guidance was $5.26 billion at the midpoint, 11.3% below analysts’ estimates.
Biopharmaceutical company Incyte Corporation NASDAQ:INCYreported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on year to $1.56 billion. On the other hand, the company’s full-year revenue guidance of $5.26 billion at the midpoint came in 11.3% below analysts’ es…